Clinically recognized dysplastic nevi: A central risk factor for cutaneous melanoma

JAMA

Volumn 277, Issue 18, 1997, Pages 1439-1444

  Tucker, Margaret A ^a,d   Halpern, Allan ^b   Holly, Elizabeth A ^c   Hartge, Patricia ^a   Elder, David E ^b   Sagebiel, Richard W ^c   Guerry IV, DuPont ^b   Clark, Wallace H ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Division of Cancer Epidemiology and Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DYSPLASTIC NEVUS; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0030912777     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.18.1439     Document Type: Article

References (44)

1. Clark WH Jr, Reimer RR, Greene MH, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions: the B-K mole syndrome. Arch Dermatol. 1978; 114:732-738.
2. Frichot BC III, Lynch HT, Guirgis HA, Harris RE, Lynch JF. New cutaneous phenotype in fa-milial malignant melanoma. Lancet. 1977;1:864-865.
3. Lynch HT, Frichot BC III, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet. 1978;15:352-356.
4. Tucker MA, Fraser MC, Goldstein AM, Elder DE, Guerry D IV, Organic SM. The risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol. 1993;100:350S-355S.
5. Elder DE, Goldman LI, Goldman SC, Greene MH, Clark WH Jr. Dysplastic nevus syndrome: a phenotypic association of sporadic melanoma. Cancer. 1980;46:1787-1794.
6. Nordlund JJ, Kirkwood J, Forget BM, et al. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res. 1986;46:1005-1009.
7. Swerdlow AJ, English J, MacKie RM, et al. Benign melanocytic naevi as a risk factor for malignant melanoma. BMJ. 1986;292:1555-1559.
8. Cristofolini M, Franceschi S, Tasin L, et al. Risk factors for cutaneous malignant melanoma in a northern Italian population. Int J Cancer. 1987;39:150-154.
9. Holly EA, Kelly JW, Shpall SN, Chiu S-H. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol. 1987; 17:459-468.
10. Roush GC, Nordlund JJ, Forget B, Gruber SB, Kirkwood JM. Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev Med. 1988;17:273-279.
11. Halpern AC, Guerry D IV, Elder DE, et al. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma: a case-control study. Arch Dermatol. 1991;127:995-999.
12. Newton JA, Bataille V, Griffiths K, et al. How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? J Am Acad Dermatol. 1993;29:989-996.
13. Kang S, Barnhill RL, Mihm MC Jr, Fitzpatrick TB, Sober AJ. Melanoma risk in individuals with clinically atypical nevi. Arch Dermatol. 1994;130: 999-1001.
14. Marghoob AA, Kopf AW, Rigel DS, et al. Risk of cutaneous malignant melanoma in patients with 'classic' atypical-mole syndrome: a case-control study. Arch Dermatol. 1994;130:993-998.
15. Schneider JS, Moore DH II, Sagebiel RW. Risk factors for melanoma incidence in prospective follow-up: the importance of atypical (dysplastic) nevi. Arch Dermatol. 1994;130:1002-1007.
16. Garbe C, Buttner P, Weiss J, et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol. 1994;102:695-699.
17. Augustsson A, Stierner U, Rosdahl I, Suurkula M. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol. 1990;71:518-524.
18. NIH Consensus Development Panel on Early Melanoma. Diagnosis and treatment of early melanoma. JAMA. 1992;268:1314-1319.
19. Weinstock MA. Dysplastic nevirevisited. J Am Acad Dermatol. 1994;30:807-810.
20. Hartge P, Holly EA, Halpern A, et al. Recognition and classification of clinically dysplastic nevi from photographs: a study of interobserver variation. Cancer Epidemiol Biomarkers Prev. 1995;4: 37-40.
21. Elder DE, Clark WH Jr, Elenitsas R, Guerry D IV, Halpern AC. The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi. Semin Diagn Pathol. 1993;10: 18-35.
22. Boice JD Jr, Lubin JH, Preston DL. EPITOME: Epidemiologic Analysis With a Personal Computer. Bethesda, Md: National Institutes of Health; 1996. NIH publication 96-3180.
23. BMDP Statistical Software. Los Angeles: University of California Press; 1992.
24. Foulds L. Neoplastic Development. New York, NY: Academic Press; 1969:41-96.
25. Clark WH Jr. The role of tumor progression in prevention of cancer and reduction of cancer mortality. In: Greenwald P, Kramer BS, Weed DL, eds. Cancer Prevention and Control. New York, NY: Marcel Dekker Inc; 1995:135-160.
26. Kinzler KW, Nilbert MC, Su LK, et al. Identification of FAP locus genes from chromosome 5q21. Science. 1991;253:661-665.
27. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159-170.
28. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. JAMA. 1994; 271:1866-1869.
29. Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. Cancer. 1995;76:1888-1901.
30. Clark WH Jr, Elder DE, Guerry D, Epstein MH, Greene MH, Van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol. 1984; 15:1147-1165.
31. Clark WH. Tumor progression and the nature of cancer. Br J Cancer. 1991;64:631-644.
32. Elder DE, Herlyn M. Antigens associated with tumor progression in melanocytic neoplasia. Pigment Cell Res. 1992;82:136-143.
33. 3 subunit with tumor progression. Cancer Res. 1990;50:6757-6764.
34. Taylor MR, Guerry D IV, Bondi EE, et al. Lack of association between intraocular melanoma and cutaneous dysplastic nevi. Am J Ophthalmol. 1984; 98:478-482.
35. Roush GC, Barnhill RL, Ernstoff MS, Kirk-wood JM. Inter-clinician agreement on the recognition of patients with cutaneous malignant melanoma: studies of melanocytic nevi, VI. Br J Cancer. 1991;64:373-376.
36. Piepkorn MW, Barnhill RL, Cannon-Albright LA, et al. A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol. 1994;30:707-714.
37. Goldstein AM, Dracopoli NC, Ho EC, et al. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevi (CMM/DN) on chromosome 1p and evidence for genetic heterogeneity. Am J Hum Genet. 1993;52:537-550.
38. Goldstein AM, Dracopoli NC, Engelstein M, Fraser MC, Clark WH Jr, Tucker MA. Linkage of cutaneous malignant melanoma/dysplastic nevi (CMM/DN) to chromosome 9p and evidence for genetic heterogeneity. Am J Hum Genet. 1994;54: 489-496.
39. MacGeoch C, Newton Bishop J, Bataille V, et al. Genetic heterogeneity in familial malignant melanoma. Hum Mol Genet. 1994;3:2195-2200.
40. Nicholls EM. Development and elimination of pigmented moles, and the anatomical distribution of primary malignant melanoma. Cancer. 1973;32: 191-195.
41. Stegmaier OC. Natural regression of the melanocytic nevus. J Invest Dermatol. 1959;32:413-421.
42. Cooke KR, Spears GFS, Skegg DCG. Frequency of moles in a defined population. J Epidemiol Commun Health. 1985;39:48-52.
43. Halpern AC, Guerry D IV, Elder DE, Trock B, Synnestvedt M, Humphreys T. Natural history of dysplastic nevi. J Am Acad Dermatol. 1993;29:51-57.
44. Cooke KR, Speare GFS, Elder DE, Greene MH. Dysplastic nevi in a population-based survey. Cancer. 1989;63:1240-1244.